Production (Stage)
Eledon Pharmaceuticals, Inc.
ELDN
$2.87
-$0.13-4.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 48.95% | 46.70% | 19.95% | 15.32% | 2.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.65% | 64.13% | 31.65% | 11.41% | 4.21% |
| Operating Income | -81.65% | -64.13% | -31.65% | -11.41% | -4.21% |
| Income Before Tax | 85.61% | 69.32% | 85.04% | 25.34% | -45.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 85.28% | 68.95% | 85.04% | 25.34% | -45.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 85.28% | 68.95% | 85.04% | 25.34% | -45.59% |
| EBIT | -81.65% | -64.13% | -31.65% | -11.41% | -4.21% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 95.28% | 80.66% | 83.10% | 67.35% | 21.96% |
| Normalized Basic EPS | 93.94% | 79.32% | 69.65% | 35.23% | -72.43% |
| EPS Diluted | 67.23% | 52.42% | 65.88% | 67.35% | 21.97% |
| Normalized Diluted EPS | 92.00% | 77.36% | 67.55% | 35.23% | -72.43% |
| Average Basic Shares Outstanding | 111.66% | 97.52% | 87.02% | 98.11% | 99.70% |
| Average Diluted Shares Outstanding | 114.76% | 101.12% | 91.30% | 98.11% | 99.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |